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PCR analysis of human renal biopsies—Ream gene regulation in
glomerulonephritis. Animal studies show that the renin-angiotensin sys-
tem contributes to hypertension, glomeruloscierosis and progressive
chronic renal failure in renal disease. Direct data on the activity of the
renal renin-angiotensin system (RAS) in human renal disease are scarce,
however. The small amount of tissue in renal biopsies and insufficient
sensitivity of analytical methods have precluded reliable measurements of
the tissue components of the HAS in the past. Due to its high sensitivity
the quantitative polymerase chain reaction (QPCR) assay today allows the
quantitation of gene transcription products in small tissue samples, for
example, renal biopsies. The clinical applicability of the PCR has raised
the interest in this methodology. We adopted quantitative PCR to study
expression and regulation of the renin gene in patients with different forms
of glomerulonephritis. For PCR a deletion mutant of the renin gene was
used as an internal standard exhibiting the same primer binding sites as
the human gene. The number of glomeruli per biopsy sample was counted
by microscopic transillumination immediately after biopsy and was used as
a reference base. Renin mRNA was expressed as fg per glomerulus.
Compared to nonaffected tissue of tumor nephrectomy samples, renin
gene expression was significantly lower in glomerulonephritic patients
without converting enzyme inhibitor (CEI) treatment, that is, 63 20 (6)
versus 250 50 (7) (P C 0.02), although plasma renin concentration was
in the normal range. Significantly higher renin mRNA expression was
found in patients with glomerulonephritis treated with CEI, that is, 210
50 (8) versus 63 20 (6) in patients not treated. The data document (i)
that quantitative PCR assays permit determination of renin gene expres-
sion in human renal disease, and that (ii) expression of the renin gene is
low early in the course of glomerulonephritis.
There is consensus that the renin-angiotensin system (RAS)
contributes to the progression of chronic renal disease and
development of glomeruloselerosis. Most of the data supporting
this notion are derived from animal models or from measure-
ments of the plasma components of the system in humans with
renal disease. There is little information, however, on the activity
of the components of the renin-angiotensin system in the kidney
of humans with renal disease. The small amount of tissue avail-
able from renal biopsies has precluded analysis in the past.
Recently the development of quantitative polymerase chain reac-
tion assays has made it possible to analyze the renin-angiotensin
system on the level of gene expression in renal biopsy samples or
even parts of it. The feasibility of this technique is demonstrated
by our measurement of renin mRNA per glomerulus in biopsies of
patients with glomerulonephritis with or without converting en-
zyme inhibitor treatment.
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Relevance of the renin-angiotensin system to human renal
disease
The role of angiotensin II as a pathogenetically relevant factor
has been confirmed in most animal models of chronic renal
damage, for example, the remnant kidney model [1], experimen-
tally-induced diabetes mellitus [2], and anti-glomerular basement
membrane glomerulonephritis [3j. In the remnant kidney model
Anderson, Rennke and Brenner observed that CEIs reduced
glomerular injury as indicated by less glomerulosclerosis and less
proteinuria; this effect was, at least in part, explained by reversal
of intraglomerular hypertension, since equal reduction in systemic
blood pressure by other antihypertensive agents failed to cause a
similar decrease in intraglomerular hypertension [4].
In humans most of the observations concerning the influence of
the RAS on chronic renal disease are based on the inhibition of
this system by ACE inhibitors. Recently, in a prospective multi-
center study, Lewis and coworkers [5] were able to demonstrate
that ACE inhibitors significantly reduced mortality and the need
for dialysis after three years of treatment in patients with type I
diabetes and nephropathy. This study showed for the first time in
humans that the renoprotective effect of the inhibitor was more
pronounced than could be explained by reduction in systemic
blood pressure alone. Several other clinical trials in the past years
did not permit a clear separation of the effects of blood pressure
reduction per se from pressure-independent effects of ACE inhib-
itors on the progression of renal disease [6].
Non-hemodynamic actions of the renin-angiotensin system
Recently, interest has been focussed on potential non-hemody-
namie actions of angiotensin II (Ang II), the effector peptide of
the RAS. It has been speculated that it may contribute to the
genesis of glomeruloselerosis via stimulation of cell proliferation
and secretion of matrix components. In chronic glomerular dis-
eases mesangial cell proliferation and extracellular matrix expan-
sion precede glomeruloselerosis [7]. Ang II induces cell hypertro-
phy and stimulates collagen and actin synthesis in cultured murine
and human adult mesangial cells, and modulates expression of
growth factors. On the other hand, blockade of the subtype 1
angiotensin II receptor with the specific receptor antagonist
losartan partially inhibits the hypertrophie/hyperplastie effect of
Ang II [8].
The recognition that local renin-angiotensin systems may be
regulated independently from the circulatory RAS introduced the
notion that the plasma RAS might not necessarily reflect the local
activity of this system such as in the diseased kidney. In the model
of ligation-induced renal ablation, increased glomei-ular renin
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gene expression could be demonstrated in para-ischemic regions
the kidney [9]. In non-ischemic tissue glomerular renin expression
was not enhanced.
The activity of the RAS in renal disease can not be determined
alone from measurements of renin. The intrarenal synthesis of
Ang II and the responsiveness of renal tissue to this peptide also
depends on the gene expression and intrarenal distribution of the
other components of the RAS [9, 10]. The importance of intra-
renal heterogeneity of gene expression is exemplified by the
angiotensin converting enzyme. In experimentally-induced diabe-
tes mellitus, expression of this gene was reduced on the whole
organ level, while it was enhanced locally in the glomeruli [11, 12].
Direct measurements of the gene expression of the components
of the RAS in renal tissue of patients with renal disease will allow
a definition of the "level of activity" of each component with
respect to: (i) particular renal structures, such as the glomerulus;
(ii) disease types; (iii) stages in the evolution of renal disease; and
(iv) prognostic relevance. In the past, the size of renal tissue
samples available at biopsy did not permit analysis by Northern
blot or nuclease protection assay. Recently, the development of
the polymerase chain reaction (PCR), with its exceptionally high
sensitivity for detection of minute amounts of DNA (or RNA),
has made biopsy material accessible to analysis. Further refine-
ments of the method allowed the quantitation of specific gene
expression of RAS components in minute human tissue samples
[13], including human kidneys [14].
Use of quantitative polymerase chain reaction assays to
determine gene expression in human biopsy material
The most important advantage of quantitative PCR, its high
sensitivity, is at the same time its largest shortcoming because it
renders standardized and reliable measurements of gene expres-
sion difficult. Even slight differences in the initial amplification
conditions may cause considerable variability in the amount of the
final amplification product. Quantitative PCR (Q-PCR) com-
prises a reverse transcription assay for transcribing total RNA into
cDNA followed by a quantitative analysis of the cDNA by PCR.
Every step of this method requires strict standardization and
control: (1) The high sensitivity of the PCR increases the possi-
bility that contamination of the sample with a few copies of the
target gene may result in false positive signals. This problem is
avoidable, however, by use of individual aliquots of each solution
which are discarded after the assay. Additionally, absence of
contamination can be controlled by PCR amplification of samples
which do not contain DNA or RNA. (2) For quantitative PCR the
use of a standard template is required. As a standard serves a
molecule which can be distinguished from the endogenous gene
by size. The standard may be shorter or longer than the endoge-
nous gene by introduction of a deletion or insertion between the
primer binding sites [13] or it may be distinguished by insertion of
an additional restriction site (Fig. 1) [15]. The standard is added
to the reaction at a known concentration and quantification can be
calculated by compairing the signal strength of the standard to the
target amplification product. Usually, the "standard molecule" is
an internal standard which may be coamplified in the PCR assay
containing the same primer annealing sequences as the endoge-
nous gene. Quantification using external standards is less often
applied since use of different genes, such as housekeeping genes,
may interfere with the accuracy because of different amplification
efficiencies of different primer pairs for target and standard cDNA
[16]. A controversy exists about the preferential use of a DNA- or
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Fig. 1. Quantitative PCR assay. Total RNA is reversely transcribed into
cDNA. Prior to the subsequent PCR an internal standard molecule,
comprising a deletion mutant of the endogenous gene, is added to the
reverse transcription assay. That mixture is then serially 1:2 diluted and
PCR is performed on each sample. Endogenous and mutant gene
amplification products are separated by size using gel electrophoresis.
Southern blot hybridization and analysis of the signal intensities of the
individual gel bands is done by scanning procedures or phosphoimager
measurements. The PCR dilution series is used for establishment of a
regression curve from which mRNA concentration can be calculated.
RNA-mutant. A RNA standard permits control for the efficiency
of the reverse transcription reaction. RNA is, however, less stable
during storage, thus influencing the reproducibility of the assay.
Use of a DNA mutant is widely applied but the efficiency of the
reverse transcription reaction for a particular gene must be
controlled [17]. This efficiency factor must be included in the
calculations of gene concentrations.
(3) A wide range of techniques and methods is used for signal
detection and analysis. Mostly, serial dilutions of the reverse
transcription assay are performed prior to PCR so that quantita-
tion can be obtained from regression curves of the signals. This
procedure is superior to singular determinations (Fig. 1). To avoid
radioactive measurements, direct scanning from Polaroids of
photographs of agarose gels is more commonly used. The gray
scale of these photographs is not linear, however, and may distort
results. The increasing use of QPCR has lead to the introduction
of chemo- or electroluminescent systems which do not depend on
radioactive nucleotides. Using these precautions QPCR allows
reliable measurements with a coefficient of variance of less than
15% or better [13].
Quantification of renin gene expression by PCR
In our studies, renin mRNA was quantified in the presence of
a defined concentration of a deletion mutant of the human renin
gene as an internal standard [13]. A deletion mutant of the human
renin gene was obtained by excision of a fragment of the renin
gene and subsequent religation using to Apa I restriction sites at
1023 and 1178 bp of the gene. The renin up- and downstream
primers used for PCR resulted in an amplification product for the
endogenous renin gene of 376 bp and 221 bp for the mutant,
respectively, using the same primer binding sites. Since primers
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spanned exon boundaries, a contamination of RNA samples with
genomic DNA could easily be detected. Amplification of genomic
DNA would result in a larger PCR product than would be
expected for RNA. According to the study by Siebert and Larrick
[171 we used a cDNA as internal standard and determined the
efficiency of reverse transcription by the recovery rate of incorpo-
rated radioactively labeled nucleotides in the reverse transcription
reaction mixture after TCA precipitation [13]. Accounting for the
efficiency of the reverse transcription efficiency, a factor of 0.51
was integrated in the calculation of renin mRNA per glomerulus;
0.5 to 1 g of total RNA [18] were reversely transcribed. For
quantification, 0.1 pg of human renin deletion mutant-cDNA was
added to the reverse transcription sample and the mixture was
serially diluted four times in 1:2 steps to establish a standard curve
for estimation of endogenous renin. Subsequently, a PCR was
performed on each sample using 28 cycles, that is well in the linear
phase of the renin PCR assay. After PCR, 25 pA of the dilution
series samples were used for gel electrophoresis (1% agarose) and
Southern hybridization on a nylon membrane (Pall, GB) by
vacuum blotting as in the study by Hirsch et al [19], using a 750 bp
long fragment of the human renin-cDNA as template. The
autoradiographic signals were counted on a phosphoimager as
PSLImm2 (Phosphoimager system, Fuji, Japan) and plotted
against the amount of total RNA as well as the number of mutant
renin molecules present in the samples of the dilution series. A
separate regression analysis was performed for the mutant and the
endogenous renin gene, respectively, We then calculated the
number of mutant molecules which corresponded to the same
signal strength as the endogenous renin gene for a certain amount
of total RNA. From that figure the total amount (fg) of renin
mRNA per sample was derived. Quantitative PCR determinations
which resulted in a correlation coefficient of less than 0.8 by
regression analysis were omitted.
Number of glomeruli as reference basis for renin gene expression
In contrast to other tissues, measurement of renin gene expres-
sion in renal biopsies is characterized by the restricted gene
expression in a limited number of structures. Renin mRNA is
predominantly localized in the juxtaglomerular apparatus adja-
cent to the glomeruli, although in some particular renal diseases,
that is, autosomal dominant polycystic kidney disease, renin
expression may also be present in extraglomerular structures [20].
In order to obtain a meaningful basis of reference for renin
mRNA we determined the number of glomeruli per biopsy
specimen directly after renal biopsy by microscopic transillumina-
tion. It is commonly assumed that glomeruli are homogenously
affected by glomerular disease, though not all to the same extent,
and that a small biopsy sample is representative for glomerulone-
phritic lesions in the kidney [21]. The biopsy samples were placed
on a sterile glass plate and the glomeruli were counted under the
microscope within 60 seconds. Control experiments showed that
renin mRNA was stable for at least 180 seconds. The median
number of glomeruli per biopsy sample was nine glomeruli. In
control tumor nephrectomy specimens renin mRNA per sample
was highly correlated to the number of glomeruli (r = 0.91).
Determination of renin mRNA in renal biopsies of patients
with glomerulonephritis
In a preliminary study the expression of renin mRNA was
determined by a quantitative polymerase chain reaction assay in
21 human kidney samples: 15 biopsies of patients with glomeru-
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Fig. 2. Renin mRNA in kidney biopsy samples. Compared to controls from
tumor nephrectomy samples, renin mRNA is significantly lower in gb-
merulonephritic patients without converting enzyme inhibitors (P < 0.02).
In comparison, patients treated with converting enzyme inhibitors had
significantly higher renin gene expression per glonierulus than patients
without CE! (P < 0.05).
lonephritis with or without angiotensin converting enzyme inhib-
itor (CE!) treatment and 6 biopsy samples from unaffected parts
of tumor nephrectomy specimens as controls.
Fifteen patients with glomerulonephritis were examined (me-
dian age 45 years, range from 23 to 62, 12 males, 3 females). Three
days prior to biopsy, patients were placed on a defined sodium
containing diet. None of the glomerulonephritic patients was on
steroids, immunsuppressive drugs or contraceptives. Glomeru-
lopathies comprised IgA nephritis, Schonlein-Henoch purpura,
epimembranous, mesangioproliferative and minimal change GN,
and non-descript mesangial scarring. Patients were subdivided
into two groups: patients with (8) or without CE inhibitors (7). In
patients without CEIs serum creatinine was 1.16 0.14 mg/dl,
blood pressure was 128 2.7 mm Hg, and proteinuria 1.77 0.7
g!day. Patients with CEIs had higher serum creatinine of 1.82
0.27, blood pressures of 143 8.4 mm Hg and proteinuria of 4.0
0.9. In glomerulonephritic patients without CEIs, a captopril
test was performed one day after renal biopsy when the patients
were still supine, and blood samples were obtained 60 and 120
minutes post-captopril for measurements of plasma renin concen-
tration.
Control kidney samples were obtained from six unaffected parts
of tumor nephrectomy specimens of normotensive patients with-
out a reduction in renal function (median age 64 years).
Renin gene expression in biopsy samples
Compared to tumor nephrectomy samples, renin gene expres-
sion was low in patients with glomerulonephritis who were not on
CE! (63 20 vs. 250 50 fg renin mRNAlglomerulus; P < 0.02;
Fig. 2). Significantly higher renin mRNA expression was found in
patients with glomerulonephritis on CE! (210 50 vs. 63 20 fg
renin mRNAlglomerulus in patients without CE!; P < 0.02).
Figure 2 shows individual renin mRNA concentrations per gb-
merulus in biopsy samples from controls and patients with gb-
merulonephritis with and without CE!. No correlation between
circulating renin and tissue level renin expression was found (Fig.
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Fig. 3. Captopril test. Active plasma renin concentration was determined
by a immunoradiometric assay (IRMA, Pasteur kit) using a monoclonal
antibody against the active site of human renin. Approximately 18 pg/mi
corresponds to 1 ng Ang I/mi/hr. Seven patients with giomerulonephritis
without CEI treatment were examined after one hour in supine rest before
and after 25 mg captopril p.o. Blood samples were drawn 60 minutes (data
not given) and 120 minutes after captopril administration.
3). The increment of post-captopril plasma renin concentration
did not correlate with renin mRNA expression. This finding
illustrates that tissue level expression of renin mRNA can not
reliably be predicted from measurements of circulating compo-
nents of the renin system. Probably due to the small number of
patients included in the study, no relationship was found between
renin mRNA and blood pressure or histological features, partic-
ularly vascular lesions.
The findings of low renin mRNA in patients with glomerulo-
nephritis without ACE inhibitor treatment do not necessarily
imply that the tissue level of renin is appropriate, since complete
evaluation of the RAS system would require that one takes into
consideration total body sodium as a determinant of renin regu-
lation. Patients on ACE inhibitors had consistently higher renin
mRNA than patients without CEI (Fig. 2), indicating an intact
renin regulation in glomerulonephritic kidneys. However, it re-
mains open whether the extent of stimulation is appropriate for
the given dosage of ACE inhibitors.
The "activity" of the renin-angiotensin system on the kidney in
glomerulonephritis cannot be assessed accurately by measure-
ment of renin mRNA alone. The other components of the system,
their synthesis, and intrarenal distribution, which determine the
efficacy of angiotensin II, remain to be investigated. A low renin
expression in glomerulonephritis, therefore, does not necessarily
exclude a pathogenetic role for renin in the development of
glomerulonephritic lesions.
Conclusions
The data document the feasibility of quantitation of mRNA in
small renal biopsy samples using the mutant template PCR
technique. Future refinements of this method, use of microdis-
secting techniques for glomerular or tubular isolation, non-
radioactive measurements, optimization of reverse transcription,
cloning procedures for internal standards, as well as of signal
recording and analysis systems will help to obviate the obstacles
which currently still impede quantitative PCR analysis. However,
this method now provides the technical possibility to analyze
expression of genes which may contribute to renal damage in
humans. The availability of sufficiently large numbers of renal
biopsies, which allows for subdivision of cohorts according to the
type or stage of human renal disease, may give clues which genes
(i) play a pathophysiological role or (ii) serve as prognostic
markers for particular diseases or disease states.
Reprint requests to Prof E. Ritz Department of Internal Medicine,
Beigheimerstr. 56a, D69115 Heidelbe,g, Germany.
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